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DNA methylationThe methylenetetrahydrofolate reductase (MTHFR) gene codes for the MTHFR enzyme which plays a key role in
the pathway of folate and methionine metabolism. Polymorphisms of genes in this pathway affect its regulation
and have been linked to lymphoma. In this studywe examinedwhether we could detect an association between
two common non-synonymousMTHFR polymorphisms, 677C N T (rs1801133) and 1298A N C (rs1801131), and
susceptibility to non-Hodgkin lymphoma (NHL) in an Australian case–control cohort. We found no significant
differences between genotype or allele frequencies for either polymorphisms between lymphoma cases and con-
trols. We also explored whether epigenetic modification ofMTHFR, specifically DNAmethylation of a CpG island
in theMTHFR promoter region, is associatedwith NHL using blood samples from patients. No difference inmeth-
ylation levels was detected between the case and control samples suggesting that although hypermethylation of
MTHFR has been reported in tumour tissues, particularly in the diffuse large B-cell lymphoma subtype of NHL,
methylation of thisMTHFR promoter CpG island is not a suitable epigenetic biomarker for NHL diagnosis or prog-
nosis in peripheral blood samples. Further studies into epigenetic variants could focus on genes that are robustly
associated with NHL susceptibility.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Non-Hodgkin lymphoma (NHL) is a diverse group of lymphoid pro-
liferative disorders and makes up 90% of all solid tumours of the im-
mune system (Shankland et al., 2012). The majority of the NHL
tumour subtypes arise from the B lymphocytes and have been defined
by the current fourth edition of the WHO classification of tumours of
haemopoietic and lymphoid tissues (Swerdlow et al., 2008). The two
most common subtypes are diffuse large B-cell lymphoma (DLBCL),
which is rapidly aggressive, and themore indolent and slowprogressing
follicular lymphoma (FL) (Shankland et al., 2012). The highest rates of
NHL are reported in the most economically developed countries such
as the United States, Australia/New Zealand and northern Europe, and
it predominantly affects white, non-hispanic men over 50 years of age
(Morton et al., 2006).CIMP, CpG island methylator
eoxyribose nucleic acid; EDTA,
a; HRM, high resolution melt;
-Hodgkin lymphoma; OR, odds
agment length polymorphism;
phism; THF, tetrahydrofolate;
edical Innovation, Queensland
.
. This is an open access article underDuring B lymphocyte development numerous mutations occur that
can disrupt normal differentiation, proliferation and survival of these
cells and thereby lead to NHL. Genetic lesions that are not lethal may
be later modulated by environmental (i.e. virus or chemical), genetic
polymorphisms or even epigenetic factors (e.g. DNA hypo- or hyperme-
thylation) that would increase risk of NHL. Recent large genome-wide
association studies (GWAS) have implicated single nucleotide polymor-
phisms (SNPs) at the human leukocyte antigen (HLA) region in both
DLBCL and NHL, as well as a number of SNPs at non-HLA loci including
transcription factors and oncogenes (Cerhan et al., 2014; Skibola et al.,
2014). In previous studies gene variants in genes involved in DNA dou-
ble-strand break and repair and the one-carbon metabolic pathway
have been associated with NHL (Skibola et al., 2007).
The one-carbon metabolic pathway, also known as the folate and
methionine metabolism pathway, is responsible for DNA synthesis
andDNAmethylation.MTHFR is themost important andwidely studied
enzymewithin one-carbon (methyl group)metabolismwhich irrevers-
ibly catalyses the conversion of 5,10-methylenetetrahydrofolate to 5-
methylTHF and is responsible for regulating the distribution of one-car-
bon moieties between the separate arms of DNA synthesis or methyla-
tion. These one-carbon transfer reactions are supported by different
nutritional co-enzymes, such as vitamin B2, B6, B12,methionine and fo-
late (Lim et al., 2007). Deficiencies of nutrients or genetic polymor-
phisms of the genes involved in this pathway have been associated
with the onset of cancer through improper DNA synthesis and repairthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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and Mason, 2000). Previous studies have reported that some genetic
variants in this pathway are associated with NHL (Skibola et al., 2007;
Lightfoot et al., 2005; Matsuo et al., 2001; Matsuo et al., 2004; Niclot
et al., 2006; Lee et al., 2007; Kim et al., 2008). Two of themostwell-stud-
ied common SNPs in the MTHFR gene are at nucleotide position 677,
where there is a cytosine to thymine base change (rs1801133;
677C N T) and at nucleotide position 1298 where there is an adenine
to cytosine base change (rs1801131; 1298A N C). Both polymorphisms
result in a missense mutation conferring a protein conformational
change with lowered enzyme activity (Robien and Ulrich, 2003; Chen
et al., 2002). As well as polymorphisms which change the activity of
MTHFR via changes in amino acid sequence, the level of expression of
the proteinmay bemodulated via polymorphisms that affect regulatory
sequences or by epigenetic modifications.
Epigeneticmodifications are changes to the genome, bymechanisms
other than changing the underlying DNA sequence that can result in
heritablemodulation of gene expression or cellular phenotype. They in-
clude potentially reversiblemodifications such as DNAmethylation, his-
tone modification and miRNA regulation that in turn affect gene
expression and protein translation. DNA methylation is one of the best
studied epigenetic modifications which occurs when a methyl group is
covalently added to the cytosine base ring at symmetric CG dinucleo-
tides in the DNA sequence. CpG islands (CGIs) at promoter regions are
protected from methylation to enable transcription and gene expres-
sion, while methylated CGIs are spread widely across the genome to si-
lence transposons and retroviruses, but also genes by recruitment of
methyl-binding proteins which participate in silencing gene transcrip-
tion (Illingworth and Bird, 2009). Aberrant DNA methylation and
deregulated gene expression is well established in NHL (Shaknovich
and Melnick, 2011). Genetic variants or polymorphisms in genes that
influence methylation may promote NHL by causing hypo- or hyper-
methylation of certain proto-oncogenes or tumour suppressor genes,
respectively (Skibola et al., 2007). DNA methylation has many clinical
applications in terms of subtype diagnosis and prognosis. It may not
only serve as a tumour biomarker but also as a therapeutic target as it
is potentially reversible with demethylating agents andmethylation in-
hibitors (Lubbert, 2000).
A study by Pike et al. in 2008 evaluated the DNAmethylation levels
at over 500 CpG islands in DLBCL tumours and found that aMTHFR CpG
island was one of the twelve that showed significant methylation in
over 85% of the tumours (Pike et al., 2008).We have previously investi-
gated the CpG island upstream of theMTHFR transcription start site and
found that increasedmethylationwas associatedwith risk of stroke, and
furthermore thiswasdetectable in bloodDNAsamples (Wei et al., 2014;
Wei et al., 2015).
The aim of this studywas to determinewhether an association exists
between polymorphisms and/ormethylation ofMTHFR and susceptibil-
ity to NHL. Previous studies assessing the gene promoter CpG island
methylation status have used tumour cells and tissue as a DNA source.
For this study only peripheral blood samples were available and thus
the aim was to also assess whether blood is a useful source for methyl-
ation detection,whichwould potentially aid in amore rapid and less in-
trusive diagnostic testing.
2. Materials and methods
2.1. Sample collection and participants.
Patients diagnosed with NHL (cases) and healthy volunteers (con-
trols) gave written consent to participate in this study and completed
a detailed questionnaire. Case samples were collected from the Gold
Coast Hospital, Princess Alexandra Hospital as well as Haematology
and Oncology clinics around Australia. Ethics was approved for sample
collection as part of the on-going Queensland University of Technology
Lymphoma Project (1400000125) by the Princess Alexandra Hospital'sHuman Research Ethics Committee (HREC/06/QPAH/047). Peripheral
blood was collected from case and control volunteers into
ethylenediaminetetra acetic acid (EDTA) vacutainer tubes and sent to
the Genomics Research Centre. Blood was stored at−20 °C on arrival
and each sample was allocated a de-identifying number and barcode.
Around 350 case samples were collected, but only 220 were suitable
for analysis taking into account exclusion criteria including non-Cauca-
sian ethnicity, unknown diagnosis or family history of haematological
malignancy. Control samples (n = 210) were collected and these
were matched to suitable cases according to age (+ or−5 years) and
sex. Out of the 220 cases, 106 (48.4%) were male and 113 (51.6%)
were female (one case was missing gender). Out of the 210 controls,
95 (45.2%) were male and 115 (54.8%) were female. The mean age of
cases in 2013 was 63.72 years with a standard deviation (SD) of 12.95
years. The mean age of controls in 2013 was 63.14 years with a SD of
13.03 years.
2.2. DNA extraction and clean-up
Genomic DNAwas extracted from peripheral blood leukocytes of all
case and control samples by the traditional salting-out method (Miller
et al., 1988). If required DNA was additionally cleaned up by
phenol:chloroform extraction and ethanol precipitation. DNA quality
and concentration was quantified using a Nanodrop spectrophotome-
ter. Working DNA samples were prepared with a final concentration
of 20 ng/μL and stored at 4 °C.
2.3. Genotyping
The following primers were used to genotype MTHFR polymor-
phisms:. MTHFR677C N T fwd: 5′-AGGACGGTGCGGTGAGAGTG-3′,
MTHFR677C N T rev: 5′-TGAAGGAGAAGGTGTCTGCGGGA-3′,
MTHFR1298A N C fwd: 5′-CACTTTGTGACCATTCCGGTTTG-3′, and
MTHFR1298A N C rev: 5′-CTTTGGGGAGCTGAAGGACTACTAC-3′. For
the 677C N T polymorphism, amplification was carried out by polymer-
ase chain reaction (PCR) on a thermocycler instrument (Veriti 96 well
Thermal Cycler, Applied Biosystems). Restriction Fragment Length Poly-
morphism (RFLP) was performed with overnight digestion with Hinf1
and the three genotypes were detected after agarose gel electrophore-
sis: CC (homozygous wild type, 198 bp), CT (heterozygote of 198 bp,
175 bp and 23 bp) and TT (homozygote mutant, 175 bp and 23 bp).
The 1298A N C polymorphism was genotyped by high resolution melt
(HRM) analysis on the Rotor-Gene Q (Qiagen) instrument with appro-
priate positive and negative controls. Amplification followed by a melt-
ing phase between 75 °C and 85 °C produced three different melting
curves representing the three genotypes: homozygous wild type AA,
heterozygote AC and homozygous mutant CC. Positive controls were
confirmed by Sanger sequencing on a 3130 Genetic Analyser (Applied
Biosystems).
2.4. Bisulfite conversion of genomic DNA and pyrosequencing
Bisulfite conversion of 500 ng of sample DNA was performed as a
preliminary step to CpGmethylation analysis using the EZ DNAMethyl-
ation-Gold™ Kit (Zymo Research) according to the manufacturer's
instructions.
The PyroMark™ CpG Assay, Hs CLCN6_01_PM (QIAGEN), was used
for the detection of methylation by PCR amplification of bisulfite
treated DNA and pyrosequencing by the PyroMark™ Q24 instrument.
The CpG island sequence of interest prior to bisulfite conversion
(GGTCACTGAGTCACCGATGGGGGCGAGGAYACGGGC) contains 3 CpG
sites where Y denotes a pyrimidine SNP, C or T. This CpG island is
shared with the 5′ transcription start site of the CLCN6 (chloride
channel 6) gene which is transcribed in the opposite direction. Ampli-
fication of bisulfite converted DNA was performed by PCR with
MTHFR primers, of which the reverse primer was biotinylated.
93G. Bradshaw et al. / Meta Gene 6 (2015) 91–95Biotinylated PCR product was immobilised to Sepharose beads, which
were captured onto filter probes and after washing were released into
the wells of the PyroMark™ Q24 Plate containing the MTHFR-specific
sequencing primer. Samples were run on a QIAGEN Q24
pyrosequencer using PyroMark™ Q24 Gold reagents and the percent
methylation levels determined at the three CpG sites in the assay
using Pyromark Q24 software.
10 samples from the case groupwere randomly selected for a repro-
ducibility test to determine reliability of the pyrosequencing assay.
Mean CpG island methylation percentages were calculated and com-
pared with mean reproducibility CpG island methylation percentages
where a range of +/−2% was acceptable. CpG1was found to show little
variation between three technical replicates, whereas methylation
levels at CpG2 and CpG3 showed N+/−2% variation and were not in-
cluded in the analysis.
2.5. Data analysis
Statistical analysis of the datawas carried out using SPSS v20.0 (SPSS
Inc., Chicago, IL, USA). Genotype frequencies were examined for Hardy–
Weinberg equilibrium in the 210 control subjects. Chi Square cross-tab-
ulation analysis was performed to examine the association between the
genotypes and alleles for each SNP and presence of NHL: the sample of
subjects was classified as either “case” or “control” and associated with
the different genotype and allele frequencies. Odds ratios and 95% con-
fidence intervals were estimated using a binary logistic regression
model for binary outcomes (1 = case, 0 = control) that controlled for
gender and age. Unadjusted P values and odds ratios were calculated
for each covariate. Adjusted P values and odds ratios were subsequently
calculated by including all the covariates. Finally a stepwise forward
conditional analysis was performed where statistical significance was
assessed after the stepwise removal of each covariate individually. P
values were calculated where a value of P b 0.05 was statistically signif-
icant. A study with a sample size of n= 200 each for cases and controls
was estimated to have approximately 70% power to detect associations
which increased NHL risk two-fold.
3. Results
3.1. Genotyping
TheMTHFR 677C N T polymorphism was genotyped by RFLP in 220
cases and 210 controls. Of these 13 case and 9 control samples failed
to amplify giving a genotyping success rate of N 94%. Genotypic frequen-
cies were found to be in Hardy–Weinberg equilibrium for the control
group (P = 0.393) with genotype numbers and frequencies in the
case and control cohorts summarised in Table 1. χ2 analysis showed
that there were no significant difference between cases and controls
for either genotypic or allelic frequencies (P = 0.445 and P = 0.95, re-
spectively). The odds ratio (OR) and 95% confidence intervals (CI) for
the allelic frequency was 0.99 (0.74–1.33) indicating no increased rela-
tive risk of NHL with presence of the 677C N T polymorphism.
TheMTHFR 1298A N C polymorphismwas genotyped by HRM in 220
cases and 210 controls, with 9 cases and 8 controls failing to amplify.Table 1
Genotype and allele frequencies ofMTHFR 677C N T and 1298A N C in a non-Hodgkin lymphom
SNP Group Genotypes
rs1801133
677C N T
CC (%) CT (%) TT (
Control 88 (43.8) 94 (46.8) 19 (
Case 97 (46.9) 85 (41.1) 25 (
AA (%) AC (%) CC (
rs1801131
1298A N C
Control 93 (46.0) 85 (42.1) 24 (
Case 94 (44.5) 92 (43.6) 25 (
P values were calculated by χ2-analysis, significance is taken at P ≤ 0.05.The control cohort genotype frequencies were found to be in Hardy–
Weinberg equilibrium (P=0.502)with genotype and allele frequencies
for the case and control cohorts also shown in Table 1. Therewas no sig-
nificant difference between genotypic and allelic frequencies of the case
and control cohorts (P = 0.948 and P = 0.82, respectively). An OR of
1.03 (0.77–1.38) indicates no increased relative risk of NHL with the
presence of the 1298A N C polymorphism.
These results show that there is no independent association be-
tween either of the MTHFR polymorphisms examined and NHL suscep-
tibility in this population cohort.
3.2. MTHFR promoter methylation
We next quantified methylation at a CpG island of the MTHFR pro-
moter in a subset of the NHL cases and controls. Cases were selected ac-
cordingly to include both NHL subtype, i.e. DLBCL and FL, and where
ample stock DNA was available. Bisulfite conversion, amplification,
and pyrosequencing were performed for 53 cases and 46 controls.
Cases and controls were not specificallymatched to each other however
they were matched in general as for the genotyping assays. Age and sex
covariates were controlled for in the logistic regression analysis. Meth-
ylation percentages were obtained for each of the three CpG sites in
the sequence of interest and results were reported in the form of a
Pyrogram™ and statistical report. As we found variation to be much
greater at CpG2 and CpG3 in technical replicates, we restricted analysis
to CpG site 1, however methylation was low at all sites (b5%).
Fig. 1 shows that these values were found to be within a normal dis-
tribution for cases and controls by frequency distribution analysis. One
case outlierwith a CpG1 percentage of 4.8%was included in the analysis.
The mean CpG1 percentage for cases was 3.21% (SD 0.57) and for con-
trolswas 3.15% (SD 0.64). An independent sample T-testwas performed
on 29DLBCL cases and 24 FL cases. Therewas no significant difference in
methylation quantity between DLBCL and FL cases (p = 0.910), there-
fore subtypes were not considered for further analysis.
3.3. Logistic regression analysis
We performed a logistic model regression analysis using SPSS for
case and control samples, including both MTHFR polymorphisms and
methylation percentage of CpG1. We controlled for covariates of age
and gender. In all analyses a p value of b0.05was considered statistically
significant. All odds ratios were calculated with 95% confidence interval
limits. Unadjusted P values were calculated for each covariate individu-
ally. The P values and odds ratios for the covariates age, gender,
677C N T, 1298A N C and CpG1 are given in Table 2. Adjusted P values
were calculated to determine significance of combined covariates and
odds ratios were calculated and are shown in Table 2. A stepwise for-
ward conditional method was used in the logistic regression model to
determine significance of covariates after the stepwise removal of
each covariate from the analysis. P values were calculated and are
given in Table 2.
These results show that there was no significant difference between
the individual or combined covariates or after stepwise removal ofa case–control population.
P Alleles P
%) C (%) T (%)
9.5) 270 (67.2) 132 (32.8)
12.1) 0.445 279 (67.4) 135 (32.6) 0.945
%) A (%) C (%)
11.9) 271 (67.1) 133 (32.9)
11.8) 0.948 142 (33.6) 133 (32.9) 0.824
Fig. 1. Frequency distribution analysis of CpG1methylation. A stem-and-leaf plot showing
distribution from the mean in cases (3.21%, SD 0.57) and controls (3.15%, SD 0.64).
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ciated susceptibility to NHL.4. Discussion
A number of case–control studies of different geographical and eth-
nic populations on the association ofMTHFR polymorphisms with NHL
susceptibility have produced conflicting results, with some showing re-
duced risk (Matsuo et al., 2001; Matsuo et al., 2004; Kim et al., 2008),
some showing increased risk (Skibola et al., 2007; Niclot et al., 2006;
Lee et al., 2007; Siraj et al., 2007; Ismail et al., 2009; Nasr et al., 2012)
and some showing no risk (Lightfoot et al., 2005; Gemmati et al.,
2004; Deligezer et al., 2006; Weiner et al., 2011). In this study we
foundno association between either the 677C N T or the 1298A N C poly-
morphisms and susceptibility to NHL in a relatively small Australian
Caucasian population, which is concordant with three previous studies
performed on Caucasians, namely Russian, Italian and British popula-
tions. Our data do not correlate with a previous Australian study, how-
ever this study showed only a marginally increased risk with 677C N T
and NHL and included subjects of Asian descent (Lee et al., 2007). Fur-
thermore, it should also be noted that because of our small sample
size the study would be unable to significantly detect odds ratios
below 2. There may be a differential distribution of the MTHFR 677TT
genotype between cases and controls (12.1% vs 9.5%), but insufficient
power means that it is not detected as significant. Genetic predisposi-
tion with respect to genetic variants may also depend on subtype, pop-
ulation, geographical region, nutritional status and environmental
factors. We did not analyse polymorphisms according to the different
NHL subtypes due to the limited sample size.Table 2
Logistic regression analysis for unadjusted and adjusted P values and odds ratios for covar-
iates between cases and controls.
Covariate Unadjusted
P
Unadjusted OR (95%
CI)
Adjusted
P
Adjusted OR
(95% CI)
Age 0.574 0.999 (0.996–1.002) 0.143 1.020 (0.993–1.047)
Gender 0.834 0.987 (0.878–1.111) 0.491 0.747 (0.326–1.712)
677C N T 0.803 0.986 (0.884–1.100) 0.580 1.196 (0.634–2.257)
1298A N
C
0.622 0.973 (0.874–1.084) 0.946 0.979 (0.526–1.821)
CpG1 0.438 0.953 (0.843–1.077) 0.262 0.685 (0.353–1.328)
P values were calculated by χ2-analysis, significance is taken at P ≤ 0.05.Deficiencies of nutrients or genetic polymorphisms of the genes in-
volved in the folate pathway have been associated with the onset of
cancer through improper DNA synthesis and repair as well as disrupted
methylation and aberrant gene expression (Choi and Mason, 2000).
MTHFR polymorphisms reduce activity of the MTHFR enzyme and the
resulting loss of methyl groups can potentially induce DNA hypomethy-
lation in blood leukocytes (Stern et al., 2000; Friso et al., 2002), as well
as CGI promoter methylation or CpG island methylator phenotype
(CIMP) in colorectal cancer (Oyama et al., 2004; Rustgi, 2007). For our
study we decided to evaluate methylation status of theMTHFR promot-
er to determine whether it influences NHL risk and whether there is a
potential association with the commonMTHFR polymorphisms in NHL
cases. However, our statistical analyses ofMTHFR CpG island methyla-
tion status both independently (Fig. 1), and in correlationwith the pres-
ence ofMTHFR polymorphisms (Table 2), showed no associations with
susceptibility to NHL.
Although Pike et al. (2008) foundmethylation ofMTHFR CpG islands
in 85% of DLBCL tumours (Pike et al., 2008), we did not detect hyperme-
thylation of MTHFR in blood in this study. Methylation-enriched ge-
nome-wide bisulfite sequencing of an FL cell line also did not find
hypermethylation ofMTHFR (Choi et al., 2010). An independent sample
T-test performed on both DLBCL and FL samples showed no significant
difference in methylation between the two groups and the MTHFR
CpG island analysed in this studywas essentially unmethylated in all in-
dividuals. Therefore whileMTHFR CpG islandsmay bemethylated in tu-
mour tissue, particularly in DLBCL, this gene does not appear to be
useful as a biomarker for NHL risk in blood samples. A caveat to this re-
sult is thatwe only investigated oneCpG island,whichwehad previous-
ly identified as increasing stroke risk (Wei et al., 2014;Wei et al., 2015).
Transcription of MTHFR is complicated, with multiple transcriptional
start sites and isoforms, so that other CpG islands or regionsmay be im-
portant depending on disease context. For example, the frequency of
MTHFR promoter methylation was found to be increased in patients
with end-stage renal disease compared to controls and this was detect-
able in peripheral blood samples (Ghattas et al., 2014). A review by Li et
al. (2012) concluded that blood-based DNA methylation patterns are
potentially useful as cancer biomarkers, although further studies need
to be carried out (Li et al., 2012). Future epigenetic studies may bewar-
ranted in genes that have been robustly implicated in NHL, such as the
HLA loci, as there is evidence for methylation of HLA genes in a range
of conditions, including some in which the differences are detectable
in blood (Graves et al., 2013; Adams et al., 2014; Hong et al., 2015).
In conclusion we have shown that the 677C N T and 1298A N C poly-
morphisms are not associated with susceptibility to NHL and that a
MTHFR promoter region CpG island is not influenced by epigenetic
DNA methylation in peripheral blood leukocytes in our Australian co-
hort of NHL patients.
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